GCIOxford Cannabinoid's breakthrough oral immunotherapy: “The initial data demonstrates excellent potential”
In this video, Vox Markets talks to Clarissa Sowemimo-Coker, CEO of (OCTP ), a biotech company focused on developing prescription medications from cannabinoids, taking Vox through the company's mission to address unmet patient needs, particularly within the US multi-billion dollar pain market. They announce their expansion into oncology and the potential of a first-in-class oral immunotherapy for solid tumors.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.